Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms

J Clin Endocrinol Metab. 2022 Jan 1;107(1):e328-e347. doi: 10.1210/clinem/dgab602.

Abstract

Context: Recent evidence suggests that vasomotor symptoms (VMS) or hot flashes in the postmenopausal reproductive state and polycystic ovary syndrome (PCOS) in the premenopausal reproductive state emanate from the hyperactivity of Kiss1 neurons in the hypothalamic infundibular/arcuate nucleus (KNDy neurons).

Objective: We demonstrate in 2 murine models simulating menopause and PCOS that a peripherally restricted kappa receptor agonist (PRKA) inhibits hyperactive KNDy neurons (accessible from outside the blood-brain barrier) and impedes their downstream effects.

Design: Case/control.

Setting: Academic medical center.

Participants: Mice.

Interventions: Administration of peripherally restricted kappa receptor agonists and frequent blood sampling to determine hormone release and body temperature.

Main outcome measures: LH pulse parameters and body temperature.

Results: First, chronic administration of a PRKA to bilaterally ovariectomized mice with experimentally induced hyperactivity of KNDy neurons reduces the animals' elevated body temperature, mean plasma LH level, and mean peak LH per pulse. Second, chronic administration of a PRKA to a murine model of PCOS, having elevated plasma testosterone levels and irregular ovarian cycles, suppresses circulating levels of LH and testosterone and restores normal ovarian cyclicity.

Conclusion: The inhibition of kisspeptin neuronal activity by activation of kappa receptors shows promise as a novel therapeutic approach to treat both VMS and PCOS in humans.

Keywords: KOR; PCOS; hot flashes; hypothalamus; menopause.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Buprenorphine / administration & dosage
  • Disease Models, Animal
  • Female
  • Hot Flashes / blood
  • Hot Flashes / drug therapy*
  • Hot Flashes / etiology
  • Humans
  • Kisspeptins / antagonists & inhibitors*
  • Kisspeptins / metabolism
  • Meloxicam / administration & dosage
  • Menopause / blood
  • Menopause / metabolism*
  • Mice
  • Neurons / drug effects
  • Neurons / metabolism
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / metabolism
  • Receptors, Opioid, kappa / agonists*
  • Receptors, Opioid, kappa / metabolism
  • Vasomotor System / drug effects

Substances

  • Kiss1 protein, mouse
  • Kisspeptins
  • Receptors, Opioid, kappa
  • Buprenorphine
  • Meloxicam